The company's patented material platform, the CorNeat EverMatrix™, is a nondegradable synthetic material that can seamlessly and permanently embed with live tissue without triggering an inflammatory response. It can reinforce soft tissue, accelerate healing, act as a membrane for guided tissue and bone regeneration, conceal irritating implants, and enable sensors to remain in contact with surrounding tissue. The technology has been proven histologically and clinically in over a dozen in-vitro and in-vivo studies, including in humans. CorNeat Vision's ophthalmic medical device uses nanoscale chemical engineering to stimulate cellular growth and leverages a virtual space under the conjunctiva that is rich with fibroblast cells, helping people suffering from corneal blindness regain their eyesight. The company's goal is to displace the use of tissue and degradable biological scaffolds in surgical procedures across diversified fields of medicine, providing safer, more reliable, long-lasting, and easier-to-handle implants.